GlassScriptPhysician profile
Thomas Paul Mason
NPI 1952306722
$4,005.19
in general payments reported to CMS, 2019-2025
29 companies · $703 in 2025
The $703 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $611 · 2021: $204 · 2022: $368 · 2023: $839 · 2024: $760 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $638.21 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $554.33 | 2021-2025 | |
| Novo Nordisk INC | $479.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $423.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $324.71 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $206.54 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $178.05 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.77 | 2023-2025 | |
| Axsome Therapeutics, INC. | $115.26 | 2023-2024 | Auvelity |
| Allergan, INC. | $100.59 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.29 | 2024-2025 | Caplyta |
| Adlon Therapeutics L.P. | $80.42 | 2019-2021 | |
| Organogenesis INC. | $72.70 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $60.66 | 2020 | |
| Mylan Specialty L.P. | $59.08 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.96 | 2019-2020 | |
| Abbott Laboratories | $52.31 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $44.94 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $41.87 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $37.95 | 2024 | Eliquis |
| Corium, LLC | $36.34 | 2022 | |
| Exact Sciences Corporation | $36.18 | 2023-2025 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $34.82 | 2019-2020 | |
| Amarin Pharma, INC. | $31.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.52 | 2025 | Trintellix |
| Insulet Corporation | $16.72 | 2023 | Omnipod |
| Corcept Therapeutics | $16.44 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.